糖尿病 z-bo 2021-11-11 496

　　"One injection can last for at least 4 months." A research team in the United States developed a new drug to control blood sugar, and it was successful in animal experiments. The researchers said that the study involves a hormone that is naturally present in the human brain and is expected to help treat diabetes in the future.

　　 Type 2 diabetes is currently one of the most common diseases, and the incidence rate is increasing year by year globally. It is characterized by a pathological increase in blood sugar. If it is not controlled, it can easily cause serious complications and even life-threatening.

　　 Previous studies have found that injecting a hormone involved in multiple biological processes-fibroblast growth factor 1 (FGF1) into the peripheral blood system of mice can produce a strong anti-diabetic effect. But to achieve this goal, a large dose of medicine is required and a large number of injections are required.

　　 In the new study, Mike Schwartz of the University of Washington and his research team changed their minds and tried to inject the hormone directly into the brains of mice and rats with type 2 diabetes. It was found that a single injection of FGF1 can keep the blood sugar levels of these animals normal for at least 4 months.

　　 Researchers claim that this treatment method works on both diet-induced obese mice and genetically induced obese mice. In addition, the therapy also proved effective in genetically induced obese rats. This long-lasting anti-diabetic effect is not affected by food intake or body weight, indicating that this improvement in blood glucose levels has nothing to do with weight loss. The study fully demonstrated that the brain can have a powerful effect on the systemic blood sugar signal transduction.

　　Schwarz said that although the therapy is currently only effective for rodents with mild diabetes, because it involves a hormone that occurs naturally in the human brain, it means that the discovery has the potential to be transformed into a clinical drug for diabetes. However, because the specific mechanism of the therapy is not yet clear, they need further research to answer this question and determine whether FGF1 has side effects.